The conduct and oversight of the progress of trials and safety of participants is achieved in many ways through development, review and performance throughout the lifecycle of the research study. In addition to the important role of the principal and co-investigator(s), the research team(s) and the individual Cancer Center Disease Programs to this endeavor, the Clinical Protocol Scientific Review and Monitoring Committee (CPSRMC) of the Cancer Center is at the core of this process. The scope and responsibilities of this Committee have evolved over time to provide rigorous and supportive review and monitoring of clinical investigations within the Cancer Center. Initially established in 1992 as the Scientific Review Board and following the then current NCI guidelines, the committee initially focused on scientific validity, study design and appropriates of statistical endpoints of protocols that did not have external peer review. Based on a desire to extend this review to all protocols in the Cancer Center, the scope and responsibilities of the committee were expanded in 1995 with a new charter and newly appointed members. More recently additional changes to enhance the process include a requirement for submission to the CPSRMC of a programmatic protocol review;adoption of a risk-based model for monitoring of clinical trials and strengthening the committee membership with additional senior researchers. In its current functions the CPSRMC reviews the scientific rationale, feasibility, study and biostatistical designs, and provides oversight to the progress of all institutional protocols to ensure adherence to initial study design, timely accruals, stopping criteria are followed and that patient safety is maintained. In addition, the CPSRMC is empowered to modify study conduct or close studies.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RTRB-Z)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
St. Jude Children's Research Hospital
United States
Zip Code
Fernandez-Pineda, I; Ortega-Laureano, L; Wu, H et al. (2016) Guidewire Catheter Exchange in Pediatric Oncology: Indications, Postoperative Complications, and Outcomes. Pediatr Blood Cancer 63:1081-5
Zhou, Sheng; Fatima, Soghra; Ma, Zhijun et al. (2016) Evaluating the Safety of Retroviral Vectors Based on Insertional Oncogene Activation and Blocked Differentiation in Cultured Thymocytes. Mol Ther 24:1090-9
Walsh, Kyle M; Whitehead, Todd P; de Smith, Adam J et al. (2016) Common genetic variants associated with telomere length confer risk for neuroblastoma and other childhood cancers. Carcinogenesis 37:576-82
Verbist, Katherine C; Guy, Cliff S; Milasta, Sandra et al. (2016) Metabolic maintenance of cell asymmetry following division in activated T lymphocytes. Nature 532:389-93
Edginton, Andrea N; Zimmerman, Eric I; Vasilyeva, Aksana et al. (2016) Sorafenib metabolism, transport, and enterohepatic recycling: physiologically based modeling and simulation in mice. Cancer Chemother Pharmacol 77:1039-52
Paugh, Steven W; Bonten, Erik J; Evans, William E (2016) Inflammasome-mediated glucocorticoid resistance: The receptor rheostat. Mol Cell Oncol 3:e1065947
Yeh, Jennifer M; Hanmer, Janel; Ward, Zachary J et al. (2016) Chronic Conditions and Utility-Based Health-Related Quality of Life in Adult Childhood Cancer Survivors. J Natl Cancer Inst 108:
Zhao, Yunqian; Nguyen, Phuong; Ma, Jing et al. (2016) Preferential Use of Public TCR during Autoimmune Encephalomyelitis. J Immunol 196:4905-14
Interiano, Rodrigo B; Malkan, Alpin D; Loh, Amos H P et al. (2016) Initial diagnostic management of pediatric bone tumors. J Pediatr Surg 51:981-5
Snaman, Jennifer M; Kaye, Erica C; Torres, Carlos et al. (2016) Parental Grief Following the Death of a Child from Cancer: The Ongoing Odyssey. Pediatr Blood Cancer 63:1594-602

Showing the most recent 10 out of 6391 publications